Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (3): 176-178
in English
| IMEMR
| ID: emr-100294
ABSTRACT
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Piperazines
/
Pyrimidines
/
Protein-Tyrosine Kinases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Type of study:
Case report
Limits:
Humans
/
Male
Language:
English
Journal:
J. Coll. Physicians Surg. Pak.
Year:
2008
Similar
MEDLINE
...
LILACS
LIS